Gabather AB (publ) (GABA) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.117x

Based on the latest financial reports, Gabather AB (publ) (GABA) has a cash flow conversion efficiency ratio of -0.117x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-331.00K ≈ $-35.62K USD) by net assets (Skr2.82 Million ≈ $303.48K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Gabather AB (publ) net asset quality index to measure how much of total assets are equity-financed.

Gabather AB (publ) - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Gabather AB (publ)'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Gabather AB (publ) investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

Gabather AB (publ) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Gabather AB (publ) ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Plantarc Bio Ltd
TA:PLNT
-0.235x
Alliance Mining Corp
V:ALM
0.002x
WINDELN.DE SE INH O.N.
F:WDL1
N/A
Medigene AG
XETRA:MDG1
-0.180x
Capella Minerals Ltd
V:CMIL
0.133x
Verney-Carron S.A
PA:MLVER
N/A
Totalindo Eka Persada Tbk PT
JK:TOPS
-0.009x
Angel Wing Metals Inc
V:AWM
-0.159x

Annual Cash Flow Conversion Efficiency for Gabather AB (publ) (2014–2025)

The table below shows the annual cash flow conversion efficiency of Gabather AB (publ) from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Gabather AB (publ) market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 Skr-863.00K
≈ $-92.87K
Skr-7.22 Million
≈ $-777.42K
8.371x +950.12%
2024-12-31 Skr-4.17 Million
≈ $-449.30K
Skr-3.33 Million
≈ $-358.15K
0.797x +103.33%
2023-12-31 Skr486.00K
≈ $52.30K
Skr-11.64 Million
≈ $-1.25 Million
-23.957x -758.22%
2022-12-31 Skr3.44 Million
≈ $369.98K
Skr-9.60 Million
≈ $-1.03 Million
-2.791x -89.90%
2021-12-31 Skr10.96 Million
≈ $1.18 Million
Skr-16.12 Million
≈ $-1.73 Million
-1.470x -209.74%
2020-12-31 Skr28.85 Million
≈ $3.10 Million
Skr-13.69 Million
≈ $-1.47 Million
-0.475x -51.21%
2019-12-31 Skr43.59 Million
≈ $4.69 Million
Skr-13.68 Million
≈ $-1.47 Million
-0.314x +75.16%
2018-12-31 Skr15.87 Million
≈ $1.71 Million
Skr-20.05 Million
≈ $-2.16 Million
-1.264x -497.58%
2017-12-31 Skr45.76 Million
≈ $4.92 Million
Skr-9.68 Million
≈ $-1.04 Million
-0.211x +0.97%
2016-12-31 Skr33.19 Million
≈ $3.57 Million
Skr-7.09 Million
≈ $-762.54K
-0.214x +50.12%
2015-12-31 Skr12.79 Million
≈ $1.38 Million
Skr-5.47 Million
≈ $-588.95K
-0.428x -141796.96%
2014-12-31 Skr8.63 Million
≈ $929.25K
Skr-2.60K
≈ $-280.32
0.000x --

About Gabather AB (publ)

ST:GABA Sweden Drug Manufacturers - Specialty & Generic
Market Cap
$1.96 Million
Skr18.19 Million SEK
Market Cap Rank
#30007 Global
#690 in Sweden
Share Price
Skr0.03
Change (1 day)
-6.29%
52-Week Range
Skr0.02 - Skr0.06
All Time High
Skr71.87
About

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer's disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment … Read more